CYH Stock Analysis: Community Health Systems | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 550m USD | 12M Return: -0.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.74M
Qual. Beats: 0
Rev. Trend: 50.7%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Community Health Systems, Inc. (NYSE: CYH) is a U.S. hospital operator that owns, leases, and runs general acute care hospitals, primarily serving non-urban and smaller metropolitan markets. The company generates revenue across both inpatient and outpatient settings, offering services such as emergency care, general and specialty surgery, critical care, obstetrics, diagnostic imaging, psychiatric care, rehabilitation, skilled nursing, and home care, alongside outpatient access points including primary care practices, urgent care centers, free-standing emergency departments, ambulatory surgery centers, and direct-to-consumer virtual health visits.
Founded in 1985 and headquartered in Franklin, Tennessee, CYH has been publicly traded since its 1991 IPO and is classified within the Health Care Facilities sub-industry of the broader Health Care sector. As a for-profit acute care operator, it competes alongside other large investor-owned hospital chains and not-for-profit health systems, with its financial performance typically shaped by factors such as inpatient admission volumes, payer mix (including Medicare and Medicaid reimbursement), labor costs, and the ongoing shift of care to outpatient and ambulatory settings.
- Hospital divestiture proceeds accelerate debt paydown
- Medicaid redeterminations elevate uncompensated care costs
- Contract labor inflation pressures hospital operating margins
| Net Income: -88.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -2.61 > 1.0 |
| NWC/Revenue: 5.61% < 20% (prev 8.20%; Δ -2.58% < -1%) |
| CFO/TA 0.01 > 3% & CFO 126.0m > Net Income -88.0m |
| Net Debt (10.6b) to EBITDA (4.96b): 2.15 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (135.0m) vs 12m ago 1.60% < -2% |
| Gross Margin: 53.66% > 18% (prev 41.74%; Δ 11.92% > 0.5%) |
| Asset Turnover: 158.7% > 50% (prev 91.10%; Δ 67.63% > 0%) |
| Interest Coverage Ratio: 4.89 > 6 (EBIT TTM 4.23b / Interest Expense TTM 864.0m) |
| A: 0.09 (Total Current Assets 3.77b - Total Current Liabilities 2.57b) / Total Assets 13.2b |
| B: -0.28 (Retained Earnings -3.63b / Total Assets 13.2b) |
| C: 0.31 (EBIT TTM 4.23b / Avg Total Assets 13.5b) |
| D: -0.10 (Book Value of Equity -1.45b / Total Liabilities 14.1b) |
| Altman-Z'' = 1.69 = BB |
| DSRI: 0.56 (Receivables 2.37b/2.47b, Revenue 21.5b/12.7b) |
| GMI: 0.78 (GM 41.74% / 53.66%) |
| AQI: 0.27 (AQ_t 0.10 / AQ_t-1 0.37) |
| SGI: 1.70 (Revenue 21.5b / 12.7b) |
| TATA: -0.02 (NI -88.0m - CFO 126.0m) / TA 13.2b) |
| Beneish M = -3.52 (Cap -4..+1) = AAA |
As of July 11, 2026, the stock is trading at USD 3.57 with a total of 750,354 shares traded. Over the past week, the price has changed by -8.46%, over one month by +20.20%, over three months by +13.33% and over the past year by -0.28%.
Current recommended Stop Loss: 3.10 (which is 13.2% or 2.9 ATR below the current price).
Community Health Systems has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold CYH.
- StrongBuy: 1
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 3.3 | -7.3% |
P/E Trailing = 1.1337
P/E Forward = 25.1889
P/S = 0.0447
P/B = 0.534
P/EG = 2.3833
Revenue TTM = 21.5b USD
EBIT TTM = 4.23b USD
EBITDA TTM = 4.96b USD
Long Term Debt = 10.1b USD (from longTermDebt, last quarter)
Short Term Debt = 126.0m USD (from shortTermDebt, last quarter)
Debt = 11.4b USD (from shortLongTermDebtTotal, last quarter) + Leases 601.0m
Net Debt = 10.6b USD (calculated: Debt 11.4b - CCE 712.0m)
Enterprise Value = 11.2b USD (549.6m + Debt 11.4b - CCE 712.0m)
Interest Coverage Ratio = 4.89 (Ebit TTM 4.23b / Interest Expense TTM 864.0m)
EV/FCF = -55.98x (Enterprise Value 11.2b / FCF TTM -200.0m)
FCF Yield = -1.79% (FCF TTM -200.0m / Enterprise Value 11.2b)
FCF Margin = -0.93% (FCF TTM -200.0m / Revenue TTM 21.5b)
Net Margin = -0.41% (Net Income TTM -88.0m / Revenue TTM 21.5b)
Gross Margin = 53.66% ((Revenue TTM 21.5b - Cost of Revenue TTM 9.96b) / Revenue TTM)
Gross Margin QoQ = none% (prev -134.6%)
Tobins Q-Ratio = 0.85 (Enterprise Value 11.2b / Total Assets 13.2b)
Interest Expense / Debt = 7.61% (Interest Expense 864.0m / Debt 11.4b)
Taxrate = 6.63% (48.0m / 724.0m)
NOPAT = 3.95b (EBIT 4.23b * (1 - 6.63%))
Current Ratio = 1.47 (Total Current Assets 3.77b / Total Current Liabilities 2.57b)
Debt / Equity = -7.81 (negative equity) (Debt 11.4b / totalStockholderEquity, last quarter -1.45b)
Debt / EBITDA = 2.15 (Net Debt 10.6b / EBITDA 4.96b)
Debt / FCF = -53.23 (negative FCF - burning cash) (Net Debt 10.6b / FCF TTM -200.0m)
Total Stockholder Equity = -1.36b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.65% (Net Income -88.0m / Total Assets 13.2b)
RoE = 6.46% (negative equity) (Net Income TTM -88.0m / Total Stockholder Equity -1.36b)
RoCE = 48.23% (EBIT 4.23b / Capital Employed (Equity -1.36b + L.T.Debt 10.1b))
RoIC = 39.36% (NOPAT 3.95b / Invested Capital 10.0b)
WACC = 7.38% (E(549.6m)/V(11.9b) * Re(13.06%) + D(11.4b)/V(11.9b) * Rd(7.61%) * (1-Tc(0.07)))
Discount Rate = 13.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.38 | Cagr: 1.00%
[DCF] Fair Price = unknown (Cash Flow -200.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.72 | # QB: 0
Revenue Correlation: 50.66 | Revenue CAGR: 9.13% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.11 | Chg30d=+20.22% | Revisions=+38% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.03 | Chg30d=+86.41% | Revisions=+38% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.60 | Chg30d=-35.55% | Revisions=-62% | GrowthEPS=-150.8% | GrowthRev=-7.1%
EPS next Year (2027-12-31): EPS=0.10 | Chg30d=N/A | Revisions=-22% | GrowthEPS=+115.7% | GrowthRev=+1.6%
[Analyst] Revisions Ratio: -4% (up=10, down=11)